The first trial of safety and toxicity shows promise for stereotactic radiosurgery as a therapeutic option for patients with localized primary renal cancer who are considered poor surgical candidates and who do not have a prior history of pelvic or abdominal radiation, according to research presented today at the American Society for Radiation Oncology’s 54th Annual Meeting (ASTRO) held in Boston, October 28 – 31,…Continue
Added by Peter Hofland, PhD on October 31, 2012 at 3:00pm — No Comments
The European Commission (EC) has approved bevacizumab (Avastin, Genentech/Roche)in combination with standard chemotherapy (carboplatin and gemcitabine) as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.
Bevacizumab is already approved by the EC as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. The additional approval of the medicine is important for women with ovarian cancer who are now able to…Continue
Added by Peter Hofland, PhD on October 31, 2012 at 1:00am — No Comments
Two studies led by The University of Texas MD Anderson Cancer Center have found that proton therapy preserves the quality of life, specifically urinary and bowel function, in men treated with this targeted radiation modality for prostate cancer.
Both studies, led by Andrew K. Lee, M.D., M.P.H., associate professor in MD Anderson's Department of Radiation Oncology, will be presented in a poster session at the 54th…Continue
Added by Peter Hofland, PhD on October 29, 2012 at 1:00pm — No Comments
The European Commission has given conditional marketing authorization for crizotinib (Xalkori®, Pfizer)in the European Union (EU) for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This ALK gene abnormality causes cancer development and growth. About 1% to 7% of those with NSCLC have the ALK gene abnormality. Patients with this form of lung cancer…Continue
Added by Peter Hofland, PhD on October 24, 2012 at 2:00pm — No Comments
Whole genome sequencing — spelling out all 3 billion letters in the human genome — “is an obvious and powerful method for advancing our understanding of pancreatic cancer,” according to a new study from TGen, Mayo Clinic and Scottsdale Healthcare published today.
The Translational Genomics Research Institute/TGen demonstrated that the use of WGS “represents a compelling solution to obtaining detailed molecular information on tumor biopsies in order to provide guidance for…Continue
Added by Peter Hofland, PhD on October 10, 2012 at 3:30pm — No Comments
Ensuring that cancer patients across Europe have equal access to the best possible cancer care, including early diagnosis, treatment and supportive care, is a medical and ethical imperative, Prof Martine Piccart (photo), the President of the European Society for Medical Oncology (ESMO), said at on Tuesday.
Speaking on the final day of the ESMO 2012 Congress in Vienna, which was attended by 16,402 persons from over 100…Continue
Added by Peter Hofland, PhD on October 2, 2012 at 1:30pm — No Comments
New findings that highlight the challenges of managing thromboembolic events in patients being treated for cancer were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012).
Venous thromboembolism causes symptoms in about 3 to 4% of cancer patients whose chemotherapy drugs are delivered via a central venous catheter, commented Fausto Roila, M.D. from Medical Oncology Department, Terni,…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 9:30pm — No Comments
For the first time, researchers have conducted a large trial in which they tested the entire genome of individual breast cancers to help personalize treatment. They released their findings at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012).
In recent years, a number of drugs have been developed that target specific genetic alterations in cancer. To choose which of these drugs are suitable for individual patients,…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 9:00pm — No Comments
Aspirin, the everyday drug taken by countless people around the world to ward off pain and reduce their risk of developing heart disease, may have a new trick up its sleeve – preventing cancer. A growing body of evidence suggests that taking aspirin may reduce an individual's chances of developing colorectal cancer and perhaps other malignancies, but whether that evidence is strong enough to outweigh the risks of prescribing it to millions of healthy people is the subject of…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 8:30pm — No Comments
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012). Renal cell carcinoma, also called kidney cancer or renal adenocarcinoma, is a type of kidney cancer that starts in the lining of the tubules in the kidney.
Prof Maria De Santis from Kaiser Franz Josef-Spital, Vienna, Chair of the ESMO 2012…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 8:00pm — No Comments
Results from the Phase III TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) demonstrating the safety and tolerability profile of tivozanib (AVEO Oncology) versus sorafenib in the first line setting for patients with metastatic renal cell carcinoma (RCC) were presented at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria (September 28 - October 2, 2012).
Added by Editorial Team on October 1, 2012 at 7:00pm — No Comments
The pivotal Phase III head-to-head study of pazopanib (Votrient®; GSK/GlaxoSmithKline) vs sunitinib (Sutent®; Pfizer) in advanced renal cell carcinoma has met its primary endpoint. In the open-label COMPARZ-study (COMParing the efficacy, sAfety and toleRability of paZopanib vs. sunitinib) pazopanib demonstrated non-inferiority to sunitinib in terms of progression free survival. Patients in the study were treated for advanced renal cell…Continue
Added by Editorial Team on October 1, 2012 at 6:00pm — No Comments
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released earlier today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. "These long awaited results constitute a further milestone in the treatment of patients with early breast cancer over-expressing HER2/neu, corresponding to a population of about 12-15% of all cases of breast cancer,” commented Prof Christoph Zielinski,…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 2:30pm — No Comments
Detailed results from an exploratory, randomized Phase II study evaluating the combination of ficlatuzumab (AVEO Oncology), a HGF inhibitory antibody, and gefitinib (Iressa; AstraZeneca) compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at…Continue
Added by Editorial Team on October 1, 2012 at 10:30am — No Comments
The results of a new phase III head-to-head study comparing crizotinib, a targeted therapy, with standard chemotherapy show that crizotinib is more effective than standard chemotherapy for patients with advanced, ALK-positive lung cancer. The results were prensented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna, Austria (September 28 - October 2, 2012).…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 6:00am — No Comments
One third of cancer patients are unaware of the fact that it is now possible to determine who is most likely to benefit from particular treatments, according to new survey data presented at ESMO 2012, the meeting of the European Society for Medical Oncology in Vienna, Austria (September 28 - October 2, 2012).…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 5:00am — No Comments
Two new studies presented at ESMO 2012, the meeting of the European Society for Medical Oncology in Vienna, Austria (September 28 - October 2, 2012) show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy. However, the trials but raise concerns about whether enough women are being offered these approaches.…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 4:00am — No Comments